COVID-19: A Message from Our CEO
"As the COVID-19 pandemic evolves, CSL remains committed to safeguarding our patients, our donors and our people. In keeping with our values-based culture, CSL has taken precautions to ensure our employees and our facilities remain safe so we can continue to deliver on our promise to patients and public health." - Paul Perreault, CEO & Managing Director, CSL LimitedRead Our Letter to Patients
Collaborating on a COVID-19 Treatment
Hear from leading plasma medicine companies about a new clinical trial for a “hyperimmune.”
CZI Donates $1.3 Million to Rare Disease Groups
NORD and EURORDIS receive partnership grants to “lift up patient advocates” during an uncertain time.
Take a Virtual Lab Tour
Go behind the scenes in Marburg, Germany, to learn how scientists remove pathogens from medicines to make them safe for patie…
Designing Clinical Trials With Patients
CSL Behring’s Deirdre BeVard will join a panel discussion on the topic December 3, but she plans to do a lot of listening.
Supporting Top Talent in Germany
CSL Behring provides 14 scholarships to several schools, including a partner university of Penn State.
The Psychology of Developing Talent
With a doctorate in psychology, Kristen Krebs applies her expertise in human behavior to her role in Global Talent Developmen…
After a Heart Attack, a 90-Day High-Risk Period
About a quarter of patients are hospitalized again within three months, according to new, real-world data shared at the Ameri…
What Does It Mean to Be Immunocompromised?
A weakened immune system can be caused by various conditions or treatments.
A Family's Fight for Access to Treatment
"Having treatment has changed her life and has given her that future that we had hoped for." - Alison, Emily's mom